International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the NAVIGATOR Trial.

International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the NAVIGATOR Trial.

<h4>Background</h4> <p>Regional differences in risk of diabetes mellitus and cardiovascular outcomes in people with impaired glucose tolerance are poorly characterized. Our objective was to evaluate regional variation in risk of new-onset diabetes mellitus, cardiovascular outcomes...

Full description

Bibliographic Details
Main Authors:	Dos Santos, M, Sharma, A, Sun, J, Pieper, K, McMurray, J, Holman, R, Lopes, R
Format:	Journal article
Language:	English
Published:	American Heart Association 2017

Similar Items

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
by: Califf, R, et al.
Published: (2008)

Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
by: Sharma, A, et al.
Published: (2016)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
by: Yates, T, et al.
Published: (2014)

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis
by: Yates, T, et al.
Published: (2014)

Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
by: Preiss, D, et al.
Published: (2012)

People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance
by: Califf, R, et al.
Published: (2003)

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
by: Currie, G, et al.
Published: (2017)

Risk factors for fatal and non-fatal cardiovascular events in 9306 subjects in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
by: Mcmurray, J, et al.
Published: (2011)

Diet and other health-related behaviors of individuals with impaired glucose tolerance, cardiovascular disease (CVD) or CVD risk: A global view from the NAVIGATOR study
by: Bales, C, et al.
Published: (2013)

Chronic obstructive pulmonary disease and cardiovascular risk: insights from the NAVIGATOR trial.
by: de Barros e Silva, P, et al.
Published: (2014)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk
by: Bethel, M, et al.
Published: (2013)

A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk.
by: Bethel, M, et al.
Published: (2013)

Frequency of abnormal glucose tolerance and the metabolic syndrome in people at increased cardiovascular disease risk screened for the NAVIGATOR trial
by: Holman, R, et al.
Published: (2003)

Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial
by: Wamil, M, et al.
Published: (2020)

High Frequency of Unrecognized Diabetes in Cardiovascular Patients: Should All Have an Oral Glucose Tolerance Test?
by: Bethel, M, et al.
Published: (2008)

Do Diuretics, Beta-Blockers, and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance? Insights from the NAVIGATOR Study
by: Shen, L, et al.
Published: (2012)

Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
by: Preiss, D, et al.
Published: (2013)

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
by: Krum, H, et al.
Published: (2010)

Relations between Baseline Physical Activity by Pedometer Counts and Future Cardiovascular Events in the NAVIGATOR Study
by: Kraus, W, et al.
Published: (2012)

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
by: Holman, R, et al.
Published: (2017)

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
by: Latini, R, et al.
Published: (2013)

Comparison of medical resources, costs, and health utilities among patients with CHD and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation Trial (ACE)
by: Mc Morrow, L, et al.
Published: (2018)

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored.
by: McMurray, J, et al.
Published: (2014)

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
by: Shen, L, et al.
Published: (2013)

Cardiologists should care about glucose: most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR
by: McMurray, J, et al.
Published: (2004)

Diabetes and impaired glucose tolerance: a review of the epidemiological and trial evidence for their role in cardiovascular risk.
by: Bowman, L, et al.
Published: (2002)

Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial
by: Liam Mc Morrow, et al.
Published: (2024-02-01)

Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: Results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial
Published: (2008)

Cardiovascular events and atherosclerosis in patients with type 2 diabetes and impaired glucose tolerance: What are the medical treatments to prevent cardiovascular events in such patients?
by: Hideki Ishii
Published: (2022-07-01)

Expert Workshop on Impaired Glucose Tolerance Held in London, UK - 29 March 1995 - Introduction
by: Holman, R
Published: (1996)

The death rate of patients with type 2 diabetes mellitus and impaired glucose tolerance from cardiovascular disease
by: E. A. Palferova
Published: (2005-04-01)

Effect of α-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance
by: McNeilly Andrea M, et al.
Published: (2011-11-01)

Predicting risk for new-onset type 2 diabetes in Chinese people with coronary heart disease and impaired glucose tolerance
by: Xu, S, et al.
Published: (2019)

Perceived Symptoms in People Living with Impaired Glucose Tolerance
by: Susanne Andersson, et al.
Published: (2011-01-01)

Improving glucose control and cardiovascular risk in general practice Type 2 diabetes.
by: Potts, N, et al.
Published: (2003)

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes.
by: Holman, R, et al.
Published: (2014)

Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance
by: Xu, S, et al.
Published: (2021)

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.
by: Gerstein, H, et al.
Published: (2006)

Influence of impaired glucose tolerance alone and combined with metabolic syndrome on long‐term risk of cardiovascular events and mortality
by: Fei Chen, et al.
Published: (2024-08-01)

Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' reply.
by: Holman, R, et al.
Published: (2014)